Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks

NCT04644484 is registered in ClinicalTrials.gov with Synermore Biologics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT04644484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04644484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks
Lead sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2020
Completion date
December 16, 2022
Enrollment
1,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

communicable disease, mononegavirales infections, rabies, rhabdoviridae infections, rna virus infections, virus diseases